학술논문

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)
Document Type
Journal
Source
BLOOD; NOV 2 2023, 142 4p. Supplement: 1
Subject
Language
English
ISSN
15280020